Severe aortic stenosis narrows the valve through which blood leaves the heart. Once the disease causes symptoms or meets other intervention criteria, replacing the valve can improve survival and function, and the replacement can be delivered through a catheter, usually from an artery in the groin, or implanted during cardiac surgery.
TAVR, short for transcatheter aortic-valve replacement, usually avoids a chest incision and heart-lung bypass, while SAVR, short for surgical aortic-valve replacement, requires an operation but can address other cardiac problems at the same sitting. Low surgical risk describes the estimated risk of an operation. It does not answer which valve strategy will serve you best over the rest of your life.
What low risk means, and what it does not#
Surgical risk scores estimate short-term operative mortality from selected variables. A low score is useful. But it cannot fully capture frailty, disability, or unusual anatomy. It cannot capture prior chest treatment, liver disease, cognition, or the person's priorities. Clinicians combine a score with clinical judgment and imaging.
Risk category is also different from age and life expectancy. A healthy person in their fifties may be low risk and have several decades in which a tissue valve could deteriorate; an older person may also be low risk but place greater value on avoiding surgery and returning home sooner. The same estimated operative risk can lead to different lifetime questions.
The low-risk trials did not compare TAVR with surgery in every patient who has severe aortic stenosis. They selected people whose anatomy and clinical circumstances made randomization reasonable. Trial eligibility therefore matters as much as the label “low risk.”
What PARTNER 3 showed at seven years#
PARTNER 3 randomized 1,000 people with severe, symptomatic aortic stenosis and low estimated surgical risk to transfemoral TAVR with a balloon-expandable valve or surgery. The mean age was about 73 years. Patients with bicuspid anatomy, anatomy unsuitable for the transcatheter device, or coronary disease requiring complex revascularization were among those excluded.
At seven years, the estimated rate of death, stroke, or valve-related, procedure-related, or heart-failure rehospitalization was 34.6% after TAVR and 37.2% after surgery. The absolute difference was -2.6 percentage points, with a 95% confidence interval from -9.0 to 3.7. The interval includes no difference and clinically relevant possibilities in both directions.
A second primary analysis ranked death, disabling stroke, nondisabling stroke, and rehospitalization in a hierarchical comparison. Its win ratio was 1.04, with a 95% confidence interval from 0.84 to 1.30. That result also did not establish a significant difference.
Individual components were similar: death occurred in 19.5% and 16.8%, stroke in 8.5% and 8.1%, and rehospitalization in 20.6% and 23.5% after TAVR and surgery, respectively; these component estimates were not proof of benefit or harm on their own. They were less precise than the trial's composite analysis and need their confidence intervals and testing plan.
Bioprosthetic valve failure was reported in 6.9% after TAVR and 7.5% after surgery. Mean valve gradients were 13.1 and 12.1 mm Hg. Those results are reassuring through the observed period, but seven years is not lifetime durability for a person who may live twenty or thirty more years.
What a second valve platform adds#
The Evolut Low Risk trial studied a self-expanding transcatheter platform rather than the balloon-expandable platform used in PARTNER 3. Among 1,414 patients in the attempted-implant population, the six-year rate of death or disabling stroke was 23.3% with TAVR and 20.4% with surgery. The confidence interval around the absolute difference crossed zero, and the comparison was not statistically significant.
Studying two platforms strengthens the conclusion that TAVR can be an effective alternative in selected low-risk patients. It does not make all transcatheter valves equivalent. Frame design, valve position, and sealing can differ. So can pacemaker risk and the ability to reach coronary arteries later.
The six-year report also deserves a time-horizon check. Later events can change a curve that looked favorable early. Attrition increases over long follow-up, and the patients still under observation may differ from those without complete data. A post hoc incomplete seven-year observation suggested more reintervention after TAVR, driven in part by aortic regurgitation, but it was not the prespecified complete six-year comparison; that signal calls for further follow-up rather than a categorical verdict.
Early tradeoffs are not the same as late tradeoffs#
TAVR commonly allows a shorter initial hospital stay and faster functional recovery. In early trial follow-up, it also reduced some complications associated with an operation, such as major bleeding and new atrial fibrillation, and these differences can be important to someone who is frail, supports another person, or wants to minimize the burden of recovery.
Surgery has different advantages. A surgeon can remove diseased tissue, enlarge a small aortic root in selected cases, or repair the aorta. The surgeon can bypass significant coronary disease or treat another valve at the same operation. Surgery can also permit a mechanical valve for an appropriate younger patient. Mechanical valves have their own lifelong anticoagulation and bleeding tradeoffs, but they change the durability discussion.
TAVR has historically carried more leakage around the prosthesis and, with some devices, a greater need for a permanent pacemaker. Even mild paravalvular regurgitation needs long follow-up. Pacemaker risk depends on valve type, anatomy, implant depth, conduction disease, and technique. Stroke, vascular injury, kidney injury, infection, and death can occur with either approach. Averages cannot identify one person's risk. Computed tomography, echocardiography, and coronary assessment turn population evidence into an individual estimate. So do vascular imaging, rhythm history, and kidney function. So do frailty and surgical review.
Anatomy can decide before preference does#
Transfemoral access requires a path from the artery to the valve that can safely accommodate the delivery system. Small, calcified, or tortuous vessels can increase vascular risk. The height of the coronary arteries, size of the aortic root, calcium pattern, and relationship between the valve and surrounding structures affect obstruction and rupture risk.
Bicuspid aortic valves often occur in younger people and can have asymmetric calcium or an associated enlarged aorta. Some people with bicuspid anatomy can undergo TAVR, but the pivotal randomized low-risk evidence is less complete than it is for the usual tricuspid anatomy. An enlarged ascending aorta may need surgical repair regardless of whether a catheter valve could be placed.
Coronary disease also changes the choice. A straightforward coronary stent and TAVR may be reasonable in one setting. Complex multivessel or left-main disease may favor bypass surgery with valve replacement. A valve frame can make future access to coronary arteries more difficult, especially after a second transcatheter valve.
Lifetime management starts with the next procedure#
Bioprosthetic valves can degenerate. A failing surgical tissue valve may sometimes receive a transcatheter valve inside it. A failing transcatheter valve may sometimes receive another transcatheter valve. Neither sequence is automatically feasible.
Placing one valve inside another can leave a small effective opening, raise gradients, impair coronary flow, or block future coronary access. Removing a transcatheter valve later is a specialized operation and can be more complex than first-time surgery. Conversely, doing surgery first uses a major operation earlier and does not guarantee that a future valve-in-valve procedure will fit.
A lifetime plan should ask:
- How long is the first valve expected to function for someone of this age and anatomy?
- Would a second valve fit without obstructing the coronaries or leaving a high gradient?
- Will future coronary angiography or stenting remain possible?
- Is the ascending aorta likely to need treatment later?
- Would a mechanical valve be an appropriate alternative?
Long-term evidence is still accumulating because contemporary low-risk TAVR is relatively recent. Device improvements help current care, yet they also mean that the longest follow-up often comes from earlier generations and techniques.
How to read the phrase “no significant difference”#
An absence of statistical significance does not prove the procedures are identical. It means the study did not demonstrate a difference under its prespecified analysis, within its precision and follow-up. The confidence interval shows the range of effects reasonably compatible with the data.
Composite endpoints can also hide tradeoffs. A death, a disabling stroke, a nondisabling stroke, and a rehospitalization do not have the same consequence. Hierarchical methods partly address that problem, while individual outcomes remain important.
Both major trials were funded by device manufacturers and tested specific products. Randomization protects the treatment comparison from many confounders. But independent follow-up, complete outcome ascertainment, adjudication, and disclosure remain important.
A practical heart-team conversation#
The ACC/AHA and ESC/EACTS guidelines emphasize multidisciplinary assessment. Their recommendations incorporate age, anatomy, and procedure feasibility. They incorporate surgical risk and informed preference. Exact age cutoffs and recommendation classes differ between guideline systems and should not replace case review.
Ask the team to explain why both procedures are or are not technically reasonable, the main short-term risks, expected recovery, device-specific pacemaker and leakage risks, and the proposed sequence if the first valve fails. Request absolute risks and the time period to which they apply.
Severe symptomatic aortic stenosis can become dangerous, so prolonged indecision is not neutral. The goal is a timely choice grounded in anatomy and lifetime planning, not allegiance to a procedure.
The consultation should also distinguish procedural success from recovery that matters to you. Survival and stroke are essential. But so are days at home, delirium, and pain. So are walking, ability to resume work or caregiving, and the burden of rehabilitation. Trials may report quality of life at fixed visits while missing fluctuations between them.
Ask how the center's outcomes compare with the populations in the trials. Operator and hospital experience can influence vascular complications, pacemaker placement, leakage, bleeding, and rescue surgery. A local estimate should state its denominator, time period, device mix, and whether it includes all attempted procedures. National averages cannot substitute for a candid center-level discussion, and a small local sample can also be unstable.
Preferences should be informed rather than assumed from age. Some older adults prioritize durability and accept surgery; some younger adults place exceptional weight on short recovery. The team should explain which options are medically reasonable before asking you to choose among them.
References#
- PARTNER 3 seven-year follow-up
- Evolut Low Risk six-year follow-up
- PARTNER 3 five-year follow-up
- 2020 ACC/AHA valvular heart disease guideline
- 2025 ESC/EACTS valvular heart disease guideline
- FDA TAVR postmarket-registry overview
For your own health, talk with your clinician.*
Questions and answers
Is TAVR better than surgery for every low-risk patient?
No. Randomized results support TAVR as an effective option in selected low-risk patients, but anatomy, age, other cardiac disease, durability, and future procedures can favor surgery.
Does a seven-year trial prove that a TAVR valve will last for life?
No. Seven-year follow-up is valuable, but it cannot establish lifetime durability for a younger person. Structural valve deterioration and reintervention require continued observation.
Why might someone need surgery even if TAVR is technically possible?
Surgery may be preferred when coronary bypass, aortic repair, another valve procedure, root enlargement, or a mechanical valve is appropriate. It may also offer a clearer lifetime sequence for some anatomies.
Is recovery always easier after TAVR?
Initial recovery is usually faster, but complications can alter the course. Vascular injury, stroke, pacemaker implantation, leakage, kidney injury, and readmission remain possible.
What should I bring to a valve consultation?
Bring a medication list, prior imaging and procedure records, questions about recovery and long-term goals, and a person who can help listen. Ask for the reasoning behind the recommended first valve and the plan for a future valve.